To evaluate the prognostic features of Ph+ CML patients treated by allogeneic BMT or by IFN, we reviewed the data of 50 consecutive pts who were transplanted between 1984 and 1988 and of 180 consecutive patients who were assigned to continuous IFN treatment between 1986 and 1988. In the BMT group, Sokal's system predicted survival (transplant-associated mortality). In the IFN group, Sokal's system, platelet count, and peripheral blood blast cell percentage predicted karyotypic response. In this group, survival was related more significantly with blast cell than with Sokal's score. The strongest predictor of survival was karyotypic response to IFN, with a 4-year survival of 94% for responders vs. 56% for non-responders
Tura, S., Russo, D., Fanin, R., Zuffa, E., Patriarca, F., Fiacchini, M., et al. (1993). PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION. LEUKEMIA & LYMPHOMA, 11(1 SUPPLEM.), 67-71.
PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION
CANTONETTI, MARIA;
1993-01-01
Abstract
To evaluate the prognostic features of Ph+ CML patients treated by allogeneic BMT or by IFN, we reviewed the data of 50 consecutive pts who were transplanted between 1984 and 1988 and of 180 consecutive patients who were assigned to continuous IFN treatment between 1986 and 1988. In the BMT group, Sokal's system predicted survival (transplant-associated mortality). In the IFN group, Sokal's system, platelet count, and peripheral blood blast cell percentage predicted karyotypic response. In this group, survival was related more significantly with blast cell than with Sokal's score. The strongest predictor of survival was karyotypic response to IFN, with a 4-year survival of 94% for responders vs. 56% for non-respondersI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
